Cubist Pharmaceuticals, Inc. Initiates Phase 2 Trial for Therapy to Reduce Blood Loss During Surgery

LEXINGTON, Mass.--(BUSINESS WIRE)--Cubist Pharmaceuticals, Inc. (Nasdaq: CBST), a leading acute care therapeutics company, announced today that it has begun dosing in the CONSERV™-1 clinical trial with ecallantide. CONSERV™-1 is a Phase 2 trial evaluating the safety, efficacy, and clinical outcomes of various doses of ecallantide for the reduction of blood loss volume during on-pump cardiothoracic surgery. The trial is expected to enroll more than 300 patients undergoing on-pump cardiothoracic surgery.